Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that MSI-H status confers therapeutic sensitivity to Dostarlimab in patients with Endometrial Carcinoma.
The European Medicines Agency (EMA) has authorized dostarlimab as a monotherapy for the treatment of adult patients with mismatch repair deficiency (dMMR) / microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.
This statement is based on a regulatory approval from the European Medicines Agency:
JEMPERLI is indicated as monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced EC that has progressed on or following prior treatment with a platinum-containing regimen.